Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
VYNE compared with RLYB: revenue, margins and what each company keeps, and the suppliers and customers both name
VYNE
VYNE Therapeutics Inc.
Change
Mkt cap
Revenue
Revenue
RLYB
Rallybio Corp
Change
Mkt cap
Revenue
Revenue
vs
Compare
VYNE
VYNE Therapeutics Inc.
vs
RLYB
Rallybio Corp
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Supply-chain overlap
Desk
News
Calendar
Saved
Search
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only VYNE
0
None
Shared
0
No disclosed counterparties: VYNE.
Only RLYB
9
JNJ
Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. ("J&J")
customer
RXRX
Recursion
customer
SNY
Kymab Limited (Sanofi)
supplier
ABCL
AbCellera Biologics
supplier
5 more · RLYB chain
›
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
VYNE
VYNE Therapeutics Inc.
Change
12.84
▼
−13.88%
Mkt cap
—
Revenue
—
Revenue
—
RLYB
Rallybio Corp
Change
15.97
▲
+0.45%
Regular session
Nov 5 '26
Mkt cap
$85.6M
Revenue
$212,000
Q1 FY26
Revenue
$858,000
FY25
vs
Compare
Regular session
Nov 5 '26
VYNE
VYNE Therapeutics Inc.
vs
RLYB
Rallybio Corp
12.84
▼
−13.88%
Price
15.97
▲
+0.45%
—
Mkt cap
$85.6M
—
Revenue
$212,000
Q1 FY26
—
Revenue
$858,000
FY25
Change
Change
VYNE
12.84
▼
−13.88%
vs
RLYB
15.97
▲
+0.45%
Regular session
Nov 5 '26